Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22498801 | 0.95 | PPARG (0.56) | PPARDPPARGKMT2ASLC6A2SLC6A3 | |
| SCHEMBL18736529 | 0.94 | KMT2A (0.54) | PPARDPPARGKMT2ASLC6A2SLC6A3 | |
| SCHEMBL18736332 | 0.91 | TDP1 (0.54) | PPARDPPARGKMT2ASLC6A2SLC6A3 | |
| SCHEMBL18736318 | 0.89 | NPC1 (0.52) | PPARDPPARGKMT2ASLC6A2SLC6A3 | |
| SCHEMBL24067532 | 0.89 | ALDH1A1 (0.48) | PPARDPPARGTDP1PPARAALDH1A1 | |
| SCHEMBL20758809 | 0.88 | KMT2A (0.60) | PPARDPPARGKMT2ASLC6A2SLC6A3 | |
| SCHEMBL30658866 | 0.88 | RAB9A (0.62) | PPARDPPARGKMT2ASLC6A2SLC6A3 | |
| SCHEMBL18736554 | 0.88 | RAB9A (0.62) | PPARDPPARGKMT2ASLC6A2SLC6A3 | |
| SCHEMBL24024852 | 0.85 | KMT2A (0.48) | KMT2ASLC6A2SLC6A3TDP1NPC1 | |
| SCHEMBL20519922 | 0.85 | PTPN1 (0.45) | PPARDPPARGKMT2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458706-B2 | Compounds and therapeutic uses thereof | AVVINITY THERAPEUTICS LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| CN-113382771-B | Compounds and therapeutic uses thereof | 阿维尼蒂治疗有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-3606558-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-3606558-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-20210353765-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | AVVINITY THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-11-18 | — | — | US | disclosed |
| US-20210353765-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | AVVINITY THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-11-18 | — | — | US | disclosed |
| US-11130730-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-09-28 | — | — | US | disclosed |
| US-11130730-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-09-28 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20200231538-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20200231538-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017060729-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060729-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060728-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | AVVINITY THERAPEUTICS LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353765-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MAVS, NFATC1, MYD88 | PPARD 1911/4885PPARG 1159/4885KMT2A 3895/4885 |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | PPARD 2022/4885PPARG 1507/4885KMT2A 3670/4885 |
| US-12458706-B2 | Compounds and therapeutic uses thereof | MAVS, NFATC1, MYD88 | PPARD 1911/4885PPARG 1159/4885KMT2A 3895/4885 |
| US-11130730-B2 | Compounds and therapeutics uses thereof | MAVS, MYD88, CD47 | PPARD 2432/4885PPARG 1681/4885KMT2A 3577/4885 |
| US-20200231538-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, CD47, STING1 | PPARD 2217/4885PPARG 1475/4885KMT2A 3714/4885 |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | PPARD 2022/4885PPARG 1507/4885KMT2A 3670/4885 |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | PPARD 2022/4885PPARG 1507/4885KMT2A 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.